Company intelligence / Profile preview

Jecho Laboratories

Frederick, Maryland, United Statesjecholabs.com ↗

Overview

Jecho Laboratories has several clinical-stage assets. Notably:

JL15003 in Phase I for glioblastoma multiforme.
JL18001 and JL19001 at IND submission stage for ALL/multiple cancers.
JL18008 IND approved for HIV.
JL20001/JLE047 IND approved for COVID‑19.
JL14001 in Phase I trial for anemia.
JL14002 in Phase III trial for AMD.Recent preclinical data were presented at AACR 2025. No pivotal or late-stage oncology results have been published yet.

Therapeutic areas: Infectious DiseasesOphthalmologyHematologyOncology
Modalities: AntibodyMonoclonal antibodyAntibody-drug conjugateFusion proteinCytokineT cell engagerOncolytic virus therapyRecombinant protein
Industry: Biotech

7 assets

Preclinical

6 more assets in the full pipeline.

No major pharmaceutical partnerships disclosed publicly as of June 2025.

Beyond the preview

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Follow clinical development from trial design and recruitment through results.

Explore licensing agreements, acquisitions, and the assets behind each deal.

Trace financing activity and the investors behind a company’s development.

Compare peer pipelines by target, modality, and therapeutic area.

Explore technology platforms and the patent landscape around relevant assets.

Connect company news and source material to the questions you’re investigating.

See how Gosset can support your research on Jecho Laboratories.